• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Surgical Wound Infections - Pipeline Review, H2 2012 Product Image

Surgical Wound Infections - Pipeline Review, H2 2012

  • ID: 2335199
  • November 2012
  • 33 pages
  • Global Markets Direct

Surgical Wound Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Surgical Wound Infections - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Surgical Wound Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Surgical Wound Infections. Surgical Wound Infections - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Surgical Wound Infections.
- A review of the Surgical Wound Infections products under READ MORE >

2
List of Tables 3
List of Figures 3
Introduction 4
REPORT COVERAGE 4
Surgical Wound Infections Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Surgical Wound Infections 6
Surgical Wound Infections Therapeutics under Development by Companies 8
Surgical Wound Infections Therapeutics under Investigation by Universities/Institutes 9
Late Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Surgical Wound Infections Therapeutics – Products under Development by Companies 12
Surgical Wound Infections Therapeutics – Products under Investigation by Universities/Institutes 13
Companies Involved in Surgical Wound Infections Therapeutics Development 14
Innocoll, Inc. 14
Durata Therapeutics Inc. 15
Surgical Wound Infections – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
dalbavancin - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
gentamicin sulfate - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
E-101 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
HO/03/06 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Symbiotic - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Surgical Wound Infections Therapeutics – Drug Profile Updates 28
Appendix 32
Methodology 32
Coverage 32
Secondary Research 32
Primary Research 32
Expert Panel Validation 32
Contact Us 33
Disclaimer 33

List of Tables
Number of Products Under Development for Surgical Wound Infections, H2 2012 6
Products under Development for Surgical Wound Infections – Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Late Stage Development, H2 2012 10
Comparative Analysis by Early Clinical Stage Development, H2 2012 11
Products under Development by Companies, H2 2012 12
Products under Investigation by Universities/Institutes, H2 2012 13
Innocoll, Inc., H2 2012 14
Durata Therapeutics Inc., H2 2012 15
Assessment by Monotherapy Products, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 20
Surgical Wound Infections Therapeutics – Drug Profile Updates 28

List of Figures
Number of Products under Development for Surgical Wound Infections, H2 2012 6
Products under Development for Surgical Wound Infections – Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Late Stage Products, H2 2012 10
Early Clinical Stage Products, H2 2012 11
Assessment by Monotherapy Products, H2 2012 16
Assessment by Route of Administration, H2 2012 17
Assessment by Stage and Route of Administration, H2 2012 18
Assessment by Molecule Type, H2 2012 19
Assessment by Stage and Molecule Type, H2 2012 20

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos